People Seek Unapproved Weight Loss Drug Online

This unique mechanism sets it apart, as it targets GLP-1, GIP, and GCG receptors, theoretically enhancing its effectiveness compared to single or dual-receptor medications.

Clinical trials show promising results, with participants losing an average of 28.7% of their body weight on the highest dose over 68 weeks. This figure is particularly striking when compared to other weight loss drugs. For instance, tirzepatide users lost an average of 15% to 22.5% over 72 weeks during clinical trials, while semaglutide users lost 10% to 15% of their body weight over 68 weeks. The efficacy of retatrutide has led some individuals to seek it out online, even though it remains in the experimental phase.

The Risks of Early Access

The FDA has issued warnings against purchasing retatrutide online, stating it’s illegal to sell unapproved medications. Compounding pharmacies, which can legally produce versions of popular drugs during shortages, are not authorized to sell retatrutide. Despite this, some individuals are turning to these sources, unaware of the potential risks involved.

Doctors strongly advise against using retatrutide before FDA approval. Dr. Richard Siegel emphasizes the importance of FDA review for safety, stating that all scientific data is carefully examined for potential harm. This process is key for identifying side effects that may not be immediately apparent during clinical trials.

For those who haven’t had success with existing weight loss medications, doctors recommend consulting a healthcare provider. Dr. Mir Ali suggests seeing an obesity medicine specialist for more tailored treatment options. It’s important to note that nearly 17% of people on current weight loss medications are considered “non-responders,” highlighting the need for alternative solutions like retatrutide once it is approved.

The Science Behind Retatrutide

Retatrutide is a triple-agonist medication, targeting three hormone receptors: GLP-1, GIP, and GCG. This approach sets it apart from GLP-1 drugs like Wegovy and Zepbound, which act on one or two receptors. Dr. Mir Ali explains that this multi-receptor action is theorized to increase the drug’s effectiveness by addressing multiple pathways involved in weight regulation.

The Dangers of Unapproved Medications

The FDA has taken a firm stance against the sale of retatrutide, emphasizing its illegal status. They have issued warning letters to companies distributing the drug and stressed that compounding pharmacies are not authorized to sell it. This is because unapproved medications may not meet the rigorous safety and efficacy standards required for FDA approval.